NASDAQ$SMLR

Semler Scientific Inc · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Semler Scientific's Q4 2021 financial results were reported with a revenue decrease and net income decline compared to the same period in 2020.

Semler Scientific reported a decrease in revenue and a significant decline in net income for Q4 2021 compared to Q4 2020. While fixed-fee license revenues increased, variable-fee license revenues and equipment/other sales decreased. The company experienced a COVID-19 related timing change in the home-testing market.

  • Q4 2021 revenues decreased by 4% to $11.5 million compared to $12.1 million in Q4 2020.
  • Net income for Q4 2021 decreased by 72% to $1.5 million, or $0.18 per diluted share, compared to $5.4 million, or $0.66 per diluted share, in Q4 2020.
  • Cost of revenues increased by 120% to $2.2 million due to a $1.2 million inventory write-down.
  • Two largest customers comprised 48.6% and 21.7% of fourth quarter revenues.

Headline financials

Total Revenue

$11.5M

Previous: $12.1M-4.4%
EPS (adj)

$0.33

Previous: $0.66-50.0%
Capital Expenditures

$57K

Previous: $46K+23.9%
Free Cash Flow

$1.6M

Previous: $5.77M-72.3%
Net Income

$1.5M

Previous: $5.39M-72.2%
Operating Income

$1.7M

Previous: $6M-71.6%
Gross Profit

$9.38M

Previous: $11.1M-15.4%
Cash & Equivalents

$37.3M

Previous: $22.1M+69.0%
Total Assets

$50.7M

Previous: $34.6M+46.3%
Stock-Based Comp

$67K

Previous: $63K+6.3%

Revenue & EPS history

Semler Scientific · Revenue · Quarterly

$11.5M

Q4 2021-4.4%vs Q4 2020
Beat estimate in 8 of 14 quarters(57%)
ActualEstimate

Forward guidance

Semler Scientific anticipates continued profitability and cash generation in 2022, with increased spending to support business growth.

Tailwinds

  • Continued profitability expected
  • Cash generation from operations expected
  • Increased spending to support anticipated growth
  • Potential for PAD risk management at the population level
  • Continued adoption of QuantaFlo® by existing and new customers

Headwinds

  • Uncertainty created by the ongoing COVID-19 pandemic
  • Potential impact of new COVID-19 variants
  • Risk factors detailed in Semler Scientific’s SEC filings
  • Dependency on insurance plans licensing cardiovascular testing products
  • Ability to successfully expand its product offering

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 6 quarterly earnings reports

Historical avg

-0.2%

Avg return

Earnings day

-2.4%

Avg return

5 days after

-5.8%

Avg return

30 days after

54%

25 / 46 earnings

Positive

+33.6%

Q4 2014

Best reaction

-33.3%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025-10.7%-16.0%-25.1%
Q2 2025-1.8%+2.0%-20.7%
Q1 2025-11.4%+17.9%-19.3%
Q4 2024+3.0%-12.4%-22.7%
Q3 2024+27.1%+29.9%+106.6%
Q2 2024-5.4%-1.7%-16.7%
Q4 2023-32.7%-36.8%-42.5%
Q3 2023+7.6%
Q2 2023+7.9%
Q1 2023+13.8%
Q4 2022+26.9%
Q3 2022-33.3%
Q2 2022+19.4%
Q1 2022-20.6%
Q4 2021-27.3%
Q3 2021-25.6%
Q2 2021-2.7%
Q1 2021+1.5%
Q4 2020+13.6%
Q3 2020+10.0%
Q2 2020-3.6%
Q1 2020-2.6%
Q4 2019+1.8%
Q3 2019+1.7%
Q2 2019+1.5%
Q1 2019-2.7%
Q4 2018+4.8%
Q3 2018-12.5%
Q2 2018+20.6%
Q1 2018+6.4%
Q4 2017+2.5%
Q3 2017+16.0%
Q2 2017-5.9%
Q1 2017+1.5%
Q4 2016+7.9%
Q3 2016-16.0%
Q2 2016+8.1%
Q1 2016-9.2%
Q4 2015-7.9%
Q3 2015+0.1%
Q2 2015-12.2%
Q1 2013+0.9%
Q4 2014+33.6%
Q3 2014-3.7%
Q2 2014-2.0%
Q1 2014+1.2%
Q4 2013
Q3 2013
Q2 2013
Q4 2012
Q3 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro